AOP-Wiki

API

All Key Events

Showing 1826 to 1850 of 1936 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

25	Agonism, Androgen receptor Short Name Agonism, Androgen receptor	1	Molecular	Nov 29, 2016	Nov 5, 2024	6 AOPs 23: Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) 376: Androgen receptor agonism leading to male-biased sex ratio 496: Androgen receptor agonism leading to reproduction dysfunction （in zebrafish） 547: Androgen receptor agonism leading to long anogenital distance in female offspring 117: Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) 495: Androgen receptor activation leading to prostate cancer
2161	Increase, Vascular disrupting effects Short Name Increase, Vascular disrupting effects	0	Individual	Aug 19, 2023	Aug 19, 2023	6 AOPs 507: Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway 508: Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway 509: Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction 510: Demethylation of PPAR promotor leading to vascular disrupting effects 511: The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects 538: Adverse outcome pathway of PFAS-induced vascular disrupting effects via activating oxidative stress related pathways
2108	Altered, white brain matter Short Name Altered, white brain matter	0	Tissue	Feb 21, 2023	Feb 21, 2023	6 AOPs 485: Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition 487: Unknown MIE altering cholesterol metabolism leading to decreased cognition 488: Increased reactive oxygen species production leading to decreased cognitive function 489: Inhibition of voltage-gated sodium channels leading to decreased cognition 525: Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory 610: Decreased thyroid hormone levels in the brain regulated via transport, metabolism and TR activation leading to decreased cognition and motor function
1532	Decrease, Cardiac contractility Short Name Decrease, Cardiac contractility	0	Organ	Jun 19, 2018	Jun 19, 2018	6 AOPs 261: L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility 479: Mitochondrial complexes inhibition leading to left ventricular function decrease via increased myocardial oxidative stress 480: Mitochondrial complexes inhibition leading to heart failure via decreased ATP production 553: Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure 556: Decreased Na/K ATPase activity leading to heart failure 558: Phosphodiesterase inhibition leading to heart failure
1613	Decrease, dihydrotestosterone (DHT) levels Short Name Decrease, DHT level	1	Tissue	Apr 10, 2019	Mar 20, 2026	6 AOPs 288: Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) 289: Inhibition of 5α-reductase leading to impaired fecundity in female fish 305: 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring 527: Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) leads to Hypospadias, increased 571: 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring 576: 5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring
1669	Increased, DNA damage and mutation Short Name Increased, DNA damage and mutation	5	Cellular	Jul 3, 2019	Aug 13, 2019	6 AOPs 303: Frustrated phagocytosis-induced lung cancer 409: Frustrated phagocytosis leads to malignant mesothelioma 416: Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway 417: Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway 443: DNA damage and mutations leading to Metastatic Breast Cancer 451: Interaction with lung resident cell membrane components leads to lung cancer
1330	Decreased, neuroplasticity Short Name Decreased, neuroplasticity	0	Molecular	Apr 13, 2017	Nov 10, 2025	6 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 221: Mental stress to depression 222: Mental stress to agitation 225: Serotonin transporter activation to agitation 224: Serotonin transporter activation to depression 604: Binding of Alpha 1-Adrenergics to Agonists Leading to Depression
1047	Increased, secretion of GnRH from hypothalamus Short Name	1	Cellular	Nov 29, 2016	Apr 6, 2026	6 AOPs 165: Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse 440: Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia 623: Activation, estrogen receptor alpha leads to persistent vaginal cornification via increased kisspeptin release 637: Activation, estrogen receptor alpha leads to increased uterine weight via earlier proliferation of cells of the uterine lining 639: Activation, estrogen receptor alpha leads to precocious puberty via increased kisspeptin release 640: Activation, estrogen receptor alpha leads to decreased fertility via prolonged estrus cycle
1928	increased，Vascular endothelial dysfunction Short Name	0	Tissue	Aug 19, 2021	Sep 1, 2021	6 AOPs 507: Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway 508: Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway 509: Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction 510: Demethylation of PPAR promotor leading to vascular disrupting effects 511: The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects 538: Adverse outcome pathway of PFAS-induced vascular disrupting effects via activating oxidative stress related pathways
465	Increased, Fatty acid influx Short Name Increased, FA Influx	1	Cellular	Nov 29, 2016	Feb 24, 2026	6 AOPs 57: AhR activation leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 58: NR1I3 (CAR) suppression leading to hepatic steatosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
619	Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Short Name	2	Molecular	Nov 29, 2016	Feb 24, 2025	6 AOPs 97: 5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline 98: 5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to decreased shelter seeking and increased predation 195: 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline 204: 5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase 568: Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Inhibition, Feeding
2405	Increase, Hepatocellular lipotoxicity Short Name Increase, Hepatocellular lipotoxicity	0	Cellular	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2406	Increase, Regenerative nodule formation Short Name Increase, Regenerative nodule formation	0	Tissue	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2407	Increase, Cirrhosis Short Name Increase, Cirrhosis	0	Organ	Feb 10, 2026	Feb 11, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2410	Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Short Name Increase, 11β-HSD1 activity	0	Molecular	Feb 18, 2026	Feb 18, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2412	Increase, Hepatic intracellular active glucocorticoids Short Name	0	Cellular	Feb 18, 2026	Feb 26, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
890	Degeneration of dopaminergic neurons of the nigrostriatal pathway Short Name	1	Organ	Nov 29, 2016	Oct 1, 2025	6 AOPs 3: Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits 471: Neuron defect induced early behavioral change 587: Inhibition of the mitochondrial complex III of nigro-striatal neurons leads to parkinsonian motor deficits 588: Inhibition of the mitochondrial complex II of nigro-striatal neurons leads to parkinsonian motor deficits 589: Inhibition of the mitochondrial complex IV of nigro-striatal neurons leads to parkinsonian motor deficits 593: Redox cycling of a chemical by mitochondria leads to degeneration of nigrostriatal dopaminergic neurons
757	Hippocampal anatomy, Altered Short Name Hippocampal anatomy, Altered	1	Tissue	Nov 29, 2016	Jul 24, 2024	6 AOPs 42: Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 8: Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 134: Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 152: Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity 300: Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 442: Binding to voltage gate sodium channels during development leads to cognitive impairment
759	Increased, Kidney Failure Short Name Increased, Kidney Failure	1	Population	Nov 29, 2016	Jan 16, 2019	6 AOPs 33: Kidney toxicity induced by activation of 5HT2C 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 413: Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure 447: Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways 622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure 472: DNA adduct formation leading to kidney failure
885	Increase, Cancer Short Name Increase, Cancer	1	Tissue	Nov 29, 2016	Aug 22, 2023	6 AOPs 141: Alkylation of DNA leading to cancer 2 139: Alkylation of DNA leading to cancer 1 505: Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway 513: Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway 474: Succinate dehydrogenase inactivation leads to cancer by promoting EMT 546: Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms
756	Hippocampal gene expression, Altered Short Name Hippocampal gene expression, Altered	1	Tissue	Nov 29, 2016	Aug 11, 2018	7 AOPs 42: Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 8: Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 134: Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 152: Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity 300: Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 458: AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals 459: AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals
896	Parkinsonian motor deficits Short Name Parkinsonian motor deficits	1	Individual	Nov 29, 2016	Mar 12, 2018	7 AOPs 3: Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits 464: Calcium overload in dopaminergic neurons of the substantia nigra leading to parkinsonian motor deficits 471: Neuron defect induced early behavioral change 587: Inhibition of the mitochondrial complex III of nigro-striatal neurons leads to parkinsonian motor deficits 588: Inhibition of the mitochondrial complex II of nigro-striatal neurons leads to parkinsonian motor deficits 589: Inhibition of the mitochondrial complex IV of nigro-striatal neurons leads to parkinsonian motor deficits 593: Redox cycling of a chemical by mitochondria leads to degeneration of nigrostriatal dopaminergic neurons
814	Occurrence, Kidney toxicity Short Name Occurrence, Kidney toxicity	1	Organ	Nov 29, 2016	Mar 4, 2022	7 AOPs 128: Kidney dysfunction by decreased thyroid hormone 256: Inhibition of mitochondrial DNA polymerase gamma leading to kidney toxicity 257: Receptor mediated endocytosis and lysosomal overload leading to kidney toxicity 258: Renal protein alkylation leading to kidney toxicity 377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS) 437: Inhibition of mitochondrial electron transport chain (ETC) complexes leading to kidney toxicity 447: Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways
944	dimerization, AHR/ARNT Short Name dimerization, AHR/ARNT	2	Molecular	Nov 29, 2016	May 31, 2025	7 AOPs 150: Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF 21: Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 310: Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR 151: AhR activation leading to preeclampsia 455: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development 456: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity 563: Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis
947	Increase, Early Life Stage Mortality Short Name Increase, Early Life Stage Mortality	2	Individual	Nov 29, 2016	Mar 22, 2018	7 AOPs 150: Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF 21: Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 455: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development 456: Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity 612: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced adenosine triphosphate 613: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via increased reactive oxygen species production 614: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced vascular endothelial growth factor